Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386203 | 1.00 | TLR7 (0.74) | TLR7NUDT1 | |
| SCHEMBL17154076 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL30895535 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL16481697 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL17154074 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL7205092 | 0.90 | TLR7 (0.66) | TLR7 | |
| SCHEMBL13728321 | 0.90 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL7205555 | 0.89 | TLR7 (0.60) | TLR7 | |
| SCHEMBL7210390 | 0.89 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL510225 | 0.89 | TLR7 (0.74) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| EP-4494709-A2 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2025-01-22 | — | — | EP | claimed |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | ENANTA PHARM INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4103567-B1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-10-23 | — | — | EP | claimed |
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | claimed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | claimed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | claimed |
| CN-115551870-A | Spirocyclic inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4103567-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2022-12-21 | — | — | EP | claimed |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Science Ireland Unlimited Company (IE) | 2022-05-05 | — | — | US | claimed |
| US-8759310-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. | 2013-08-08 | — | — | US | claimed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| JP-2009533348-A | — | — | 2009-09-17 | — | — | JP | claimed |
| CN-101460178-A | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS INC (US) | 2009-06-17 | — | — | CN | claimed |
| EP-2021008-A2 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | Idera Pharmaceuticals, Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | claimed |
| WO-2007117686-A2 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | TLR7 2/4885NUDT1 100/4885 |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, NR1H4 | TLR7 1963/4885NUDT1 1633/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | TLR7 976/4885NUDT1 445/4885 |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | HAVCR2, XDH, PYGL | TLR7 842/4885NUDT1 220/4885 |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | HAVCR2, PYGL, SLC10A1 | TLR7 1499/4885NUDT1 1297/4885 |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | TLR7 2/4885NUDT1 687/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TLR7 1499/4885NUDT1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.